Skip to main content
Quest Diagnostics

COVID-19 Real World Data infrastructure (CRWDi): A Big Data Resource for Study of Immunocompromised Patient Populations

SeroNet Investigators Meeting 2024

NCI (National Cancer Institute) Serological Sciences Network for COVID-19

New York, NY March 26- 2024

Oral presentation: COVID-19 Real World Data infrastructure (CRWDi): A Big Data Resource for Study of Immunocompromised Patient Populations

Authors: Crawford JM, Penberthy L, Pinto L3, Althoff KN, Assimon M5, Boehmer T, Cohen O, Gillim L, Gundlapalli A, Hammonds T, Kapur S, Kaufman HW, Kwasny D, Liew JW, Meyer III WA, Reynolds SL, Ritchey M, Schleicher CB, Subbiah S, Theruviparampil C, Wallace ZS, Warner JL, Yoon N, Ziemba YC

Specialty: Infectious disease, COVID-19, Population Health

Related content

Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Conference Presentation
SARS-CoV-2 mRNA Vaccination Affects Antibody and Cellular Immune Responses After B-Cell Depletion Therapies

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.